1. Home
  2. FRO vs DNTH Comparison

FRO vs DNTH Comparison

Compare FRO & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Frontline Plc

FRO

Frontline Plc

HOLD

Current Price

$40.90

Market Cap

4.8B

ML Signal

HOLD

Logo Dianthus Therapeutics Inc.

DNTH

Dianthus Therapeutics Inc.

HOLD

Current Price

$82.49

Market Cap

4.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FRO
DNTH
Founded
1985
2015
Country
Cyprus
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.8B
4.5B
IPO Year
1995
2018

Fundamental Metrics

Financial Performance
Metric
FRO
DNTH
Price
$40.90
$82.49
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
13
Target Price
$37.67
$121.00
AVG Volume (30 Days)
3.3M
926.4K
Earning Date
05-22-2026
05-06-2026
Dividend Yield
4.85%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,036,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$29.48
P/E Ratio
$34.05
N/A
Revenue Growth
N/A
N/A
52 Week Low
$16.25
$18.08
52 Week High
$40.74
$96.50

Technical Indicators

Market Signals
Indicator
FRO
DNTH
Relative Strength Index (RSI) 69.80 48.32
Support Level $33.68 $79.27
Resistance Level N/A $92.41
Average True Range (ATR) 1.61 5.51
MACD 0.55 -0.15
Stochastic Oscillator 99.16 57.80

Price Performance

Historical Comparison
FRO
DNTH

About FRO Frontline Plc

Frontline PLC is an international shipping company engaged in the seaborne transportation of crude oil and oil products. Group operates through the tankers segment. The tankers segment includes crude oil tankers and product tankers. Its geographical area of operation includes Arabian Gulf, West African, the North Sea, and the Caribbean. Frontline earns revenue through voyage charters, time charters, and a finance lease. It is also involved in the charter, purchase, and sale of vessels.

About DNTH Dianthus Therapeutics Inc.

Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.

Share on Social Networks: